Literature DB >> 18698691

Abrupt onset of type 1 diabetes mellitus during recombinant interferon-alpha 2b therapy in a patient with chronic hepatitis B.

Yuan-Yuan Lv1, Bing-Yin Shi, Hui Guo.   

Abstract

We describe a case of a 33-year-old female patient with chronic hepatitis B who developed type 1 diabetes mellitus (DM) after a 13-mo period of treatment with recombinant human interferon-alpha (IFN-alpha) 2b. The patient presented with polydipsia, polyuria, hyperglycemia, diabetic ketoacidosis, combined with C-peptide secretion deficiency and positive islet cell autoantibody (ICAb). IFN-alpha 2b treatment was terminated and instead insulin treatment was initiated. Five months after cessation of the recombinant human IFN-alpha 2b therapy, the patient remained insulin-dependent. Her serum HBV DNA became negative and serum transaminase returned to the normal level after a 10-mo period of IFN therapy. Type 1 DM induced by IFN-alpha is relatively rare in patients with chronic hepatitis B. We should pay more attention to patients on IFN-alpha therapy to avoid destruction of pancreatic beta cells. This is the first case report from China.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18698691      PMCID: PMC2738801          DOI: 10.3748/wjg.14.4713

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  15 in total

1.  Autoimmunity against pancreatic islets and other tissues before and after interferon-alpha therapy in patients with hepatitis C virus chronic infection.

Authors:  C Betterle; P Fabris; R Zanchetta; B Pedini; G Tositti; E Bosi; F de Lalla
Journal:  Diabetes Care       Date:  2000-08       Impact factor: 19.112

2.  Evaluation of factors controlling glucose tolerance in patients with HCV infection before and after 4 months therapy with interferon-alpha.

Authors:  T Konrad; S Zeuzem; P Vicini; G Toffolo; D Briem; J Lormann; G Herrmann; A Berger; K Kusterer; G Teuber; C Cobelli; K H Usadel
Journal:  Eur J Clin Invest       Date:  2000-02       Impact factor: 4.686

Review 3.  Type 1 diabetes mellitus in patients with chronic hepatitis C before and after interferon therapy.

Authors:  P Fabris; A Floreani; G Tositti; D Vergani; F De Lalla; C Betterle
Journal:  Aliment Pharmacol Ther       Date:  2003-09-15       Impact factor: 8.171

4.  Development of type 1 diabetes mellitus during interferon alfa therapy for chronic HCV hepatitis.

Authors:  P Fabris; C Betterle; A Floreani; N A Greggio; F de Lazzari; R Naccarato; M Chiaramonte
Journal:  Lancet       Date:  1992-08-29       Impact factor: 79.321

5.  Islet cell and thyroid antibody prevalence in patients with hepatitis C virus infection: effect of treatment with interferon.

Authors:  S Piquer; C Hernández; J Enriquez; A Ross; J I Esteban; J Genescà; E Bonifacio; M Puig-Domingo; R Simó
Journal:  J Lab Clin Med       Date:  2001-01

6.  Interferon-alpha improves glucose tolerance in diabetic and non-diabetic patients with HCV-induced liver disease.

Authors:  T Konrad; P Vicini; S Zeuzem; G Toffolo; D Briem; J Lormann; G Herrmann; D Wittmann; T Lenz; K Kusterer; G Teuber; C Cobelli; K H Usadel
Journal:  Exp Clin Endocrinol Diabetes       Date:  1999       Impact factor: 2.949

7.  Onset of type 1 diabetes mellitus during peginterferon alpha-2b plus ribavirin treatment for chronic hepatitis C.

Authors:  Raffaele Cozzolongo; Corrado Betterle; Paolo Fabris; Maria Paola Albergoni; Elsa Lanzilotta; Onofrio G Manghisi
Journal:  Eur J Gastroenterol Hepatol       Date:  2006-06       Impact factor: 2.566

8.  Induction of autoantibodies to the adrenal cortex and pancreatic islet cells by interferon alpha therapy for chronic hepatitis C.

Authors:  B Wesche; E Jaeckel; C Trautwein; H Wedemeyer; A Falorni; H Frank; A von zur Mühlen; M P Manns; G Brabant
Journal:  Gut       Date:  2001-03       Impact factor: 23.059

9.  Simultaneous development of diabetic ketoacidosis and Hashitoxicosis in a patient treated with pegylated interferon-alpha for chronic hepatitis C.

Authors:  Aspasia S Soultati; Spyridon P Dourakis; Alexandra Alexopoulou; Melanie Deutsch; Athanasios J Archimandritis
Journal:  World J Gastroenterol       Date:  2007-02-28       Impact factor: 5.742

10.  A case of pegylated interferon alpha-related diabetic ketoacidosis: can this complication be avoided?

Authors:  G Tosone; G Borgia; I Gentile; R Cerini; M C D Conte; R Orlando; M Piazza
Journal:  Acta Diabetol       Date:  2007-08-26       Impact factor: 4.280

View more
  1 in total

1.  Effects of Tenofovir Combined with Recombinant Human Interferon α-2b on Negative Conversion Rate, Liver Function, Immune Status, and Drug Safety in Patients with Chronic Hepatitis B: A Systematic Review and Meta-Analysis.

Authors:  Hui Zhang; Jianchun Xian; Yang Li; Li Xiao; Lu Wang
Journal:  Evid Based Complement Alternat Med       Date:  2022-06-30       Impact factor: 2.650

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.